Takeda presented promising data on its ulcerative colitis and Crohn's disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla.
The data suggests Entyvio is most effective in biologic-naïve patients where other therapies were ineffective.
Takeda conducted two post-hoc analyses of gemini data in UC patients. In those analyses, symptomatic improvements were documented in two-week intervals. Researchers measured patient-reported outcomes scores and for Mayo Clinic subscores for rectal bleeding and stool frequency.
Researchers found the greatest reported improvements were in patients who were biologically naïve. Such patients saw improvements as early as the second week.
Ontario, Canada-based Robarts Research Institute's Director of Robarts Clinical Trials Brian Feagan, MD, said in a release, "The resolution of patient-reported symptoms for both ulcerative colitis and Crohn’s disease examined in these analyses signifies important treatment goals for patients and key indicators for response to treatment for physicians. The results support Entyvio's value as a therapy for ulcerative colitis and Crohn’s disease with a recognized safety profile and short-and long-term efficacy."